Krasimira A Rozenova, MD, PHD | |
20 York St, New Haven, CT 06510-3220 | |
(203) 688-4242 | |
Not Available |
Full Name | Krasimira A Rozenova |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 20 York St, New Haven, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801381207 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Krasimira A Rozenova, MD, PHD 20 York St, New Haven, CT 06510-3220 Ph: (203) 688-4242 | Krasimira A Rozenova, MD, PHD 20 York St, New Haven, CT 06510-3220 Ph: (203) 688-4242 |
News Archive
Inappropriate use of camphor-containing products may be a common and underappreciated cause of seizures in young children, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University.
Postmenopausal women who consume even moderate amounts of alcohol may face an increased risk of breast cancer, particularly if their cancer is fueled by the hormones estrogen or progesterone, according to a data analysis by researchers at Boston's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard School of Public Health.
St. Jude investigators have mapped out many of the dynamic genetic and biochemical changes that make up a cell's response to a shortage of a molecule called Coenzyme A (CoA), a key player in metabolism.
Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.
› Verified 1 days ago